Focus: Zymeworks is a public biotech company specializing in in silico biologics development, focused on oncology and immunology through antibody-drug conjugates (ADCs) and engineered antibodies. With 501-1,000 employees and a public listing (ZYME), the company operates at mid-cap biotech scale.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Stable — net +4 jobs in 30d
8 added, 4 removed. Backfill posture.
Zymeworks offers meaningful scientific opportunity in ADC development with recent regulatory validation, but significant financial deterioration and severely limited current hiring create execution risk and entry difficulty.
Most advanced program (Phase 3) with potential for near-term regulatory decision; represents most de-risked asset in pipeline.
Help build intelligence for Zymeworks
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Zymeworks's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Zymeworks Presents New Preclinical Data at AACR 2026 - GlobeNewswire
Zymeworks Presents New Preclinical Data at AACR 2026 GlobeNewswire
Zymeworks announces leadership appointments - The Pharma Letter
Zymeworks announces leadership appointments The Pharma Letter
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate - GlobeNewswire
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate GlobeNewswire
FDA speeds review of Zymeworks ovarian cancer drug ZW191 - Stock Titan
FDA speeds review of Zymeworks ovarian cancer drug ZW191 Stock Titan
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate - GlobeNewswire
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate GlobeNewswire
Zymeworks Shares Its Design Rationale (And Wins) In Early-Phase ADC Trials - Clinical Leader
Zymeworks Shares Its Design Rationale (And Wins) In Early-Phase ADC Trials Clinical Leader
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo